Primary Squamous Cell Carcinoma of the Liver is Rare but Hostile: Case Series and Comprehensive Review of the Literature.

Primary squamous cell carcinoma (SCC) of the liver is an uncommon cancer type. Only dozens of such cases have been reported in the literature. We reviewed three cases with primary SCC of the liver in a single center from January 2013 to October 2019. One case was positive for hepatitis B infection and simultaneously diagnosed with sigmoid adenocarcinoma and liver cyst. The second patient presented with hepatolithiasis. The remaining one had no history of prior liver insult, hepatic infection or any pre-existing hepatic cysts. Two cases had a long survival of more than one year through chemotherapy, or radical surgery plus transarterial chemoembolization. We also found 25 patients with primary hepatic SCC in the Surveillance, Epidemiology and End Results (SEER) database from 1997 to 2016. The median age was 67 years (range 33-87 years). The median overall survival and disease-specific survival were 7.7 months (range 0.0-76.0 months) and 2.0 months (range 0.0-20.0 months), respectively. Furthermore, patients receiving surgery had a longer median OS (20.0 versus 6.0 months, P = 0.016) and DSS (48.0 versus 8.0 months, P = 0.03) than those receiving palliative treatment. Only 20% of all cases survived for more than a year. Although primary SCC of the liver has an unfavorable prognosis, radical surgery and systematic treatment might be helpful for clinical management.

Introduction

Primary squamous cell carcinoma (SCC) of the liver is a rare and easily misdiagnosed disease.1 Only dozens of such cases have been reported in the literature since the 1970s.1–10 The carcinogenesis and pathogenesis of primary hepatic SCC has not been elucidated to date, but this disease is regularly considered to be associated with hepatic teratoma, congenital cyst of the liver or the long-term inflammation or metaplasia of biliary epithelial cells.3 Although some cases with the primary SCC of the liver have been successfully managed with initial surgery and chemotherapy, there is no standard care for this disease.2,6 As an aggressive cancer, the prognosis of this tumor is extremely unfavorable with an overall survival (OS) of less than 12 months.1–10 In this retrospective study, we reported three cases of primary SCC of the liver in a single center from January 2013 to October 2019 and analyzed their clinical and pathological characteristics, treatment and prognosis. We also reviewed all cases with the primary SCC of the liver from the Surveillance, Epidemiology and End Results (SEER) database from 1997 to 2016.

Patients and Data

Patients

The retrospective case series study included three pathologically confirmed primary SCC of the liver at The First Affiliated Hospital of Shandong First Medical University from January 2013 to October 2019. These primary SCC of the liver account for 0.5% of all primary hepatic malignancies including 495 patients with hepatocellular carcinoma, 103 with intrahepatic cholangiocarcinoma, and one with adenosquamous carcinoma of the liver. A total of 78 pathologically confirmed patients with metastatic SCC of the liver also were diagnosed during the same period. The clinical data including clinical symptoms, signs, pathological diagnosis, radiological findings, laboratory analyses, treatments, and outcome were obtained by local investigators from the hospital’s electronic medical records according to previously designed standardized data collection forms. Pathological diagnosis including immunohistochemistry (IHC) was independently reviewed by two pathologists. Written informed consent for publication was provided by all patients, which was in accordance with the Helsinki Declaration. The approval was obtained from the independent research ethics of The First Affiliated Hospital of Shandong First Medical University (NO: YXLL-KY-2020-007) to publish the case details and conduct this research.

We also investigated all primary SCC of the liver in SEER database released in November 2019, which includes data from 18 population-based registries (1976–2016) covering approximately 28% of cancer patients in the United States. Tumor location, grade, and histology were recorded according to the International Classification of Diseases for Oncology Version 3 (ICD-O-3). The inclusion criteria that were used to identify eligible patients included: age between 18 and 79 years, primary tumor location of the liver (ICD-O-3 site code C22), only one primary site or more primaries, pathologically confirmed squamous cell carcinoma (8070/3, 8071/3, 8072/3, 8073/3, and 8076/3), stages I–IV tumors according to the American Joint Committee on Cancer (AJCC) staging system, 7th version. Finally, 24,508 cases with squamous cell carcinoma and 724,508 cases with primary hepatic malignancy were identified from the SEER database.

Results

Case Presentation from the Single Center

Case 1

A 79-year-old man was initially admitted to The First Affiliated Hospital of Shandong First Medical University in February 2012, complaining of the loss of appetite and weakness for nearly 3 months. Twenty years ago, he was diagnosed with sigmoid adenocarcinoma and received surgery and postoperative adjuvant chemotherapy. He had no history of any hepatitis virus infection. He had a long history of alcohol consumption, but not gastrointestinal bleeding. On admission, the liver was not touched by physical examination. The platelet count (PLT), prothrombin time (PT), activated partial thromboplastin time (APTT), and liver function tests including alanine aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL) were normal (Table 1). He also had normal levels of alpha fetoprotein (AFP) and SCC antigen, but the levels of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) were elevated. Computed tomography (CT) revealed multiple low-density lesions with unclear boundary and mild to moderate enhancement in the liver accompanied by liver cysts and gallbladder stones, without portal vein invasion or splenomegaly (Figure 1A and B). Ultrasonography (US)-guided liver biopsy showed a pathological diagnosis of SCC by hematoxylin-eosin (HE) staining. IHC analysis showed that CK7, hepatocyte and CK19 staining were negative but p63 expression was positive (Figure 1C–E). Ventana IHC analysis (Clone NO. SP263) indicated that PD-L1 expression on tumor cells and tumor-associated immune cells was negative (Figure 1F and G). Given that no lesions in the lungs, gastrointestinal tract or other organs were observed, primary SCC of the liver was diagnosed. The patient did not receive surgery, radiotherapy, transarterial chemoembolization (TACE), or tyrosine kinase inhibitor treatment. He was treated with SOX chemotherapy regimen (Oxaliplatin 200 mg, day 1, and S-1 50 mg twice per day, d1-14, q21d) for 4 cycles. However, the patient stopped his therapy 3 months later. Subsequently, his disease progressed, and he rejected any anticancer therapies and died at the 20th month of the initial diagnosis.

Table 1

Summary of three Patients with SCC of the Liver in Our Hospital

	Patient 1	Patient 2	Patient 3
Gender	Male	Male	Female
Age, years	79	47	79
Alcohol consumption	+	+	-
HbsAg	-	+	-
HCV-Ab	-	-	-
Liver cyst	+	-	-
Hepatolithiasis	+	+	-
Gastrointestinal hemorrhage	-	-	-
PLT	Normal	Normal	Normal
AST/ALT, U/L	25.3/22.8	673/867	17.8/21.3
TBIL/DBIL, umol/L	7.7/3.7	15.7/7.5	9.6/5.0
PT/APTT, second	10.2/29.4	10.0/24	11.8/26.5
AFP/CEA	1.2/9.38	3.34/1.55	0.78/1.82
SCC/CYFRA21-1	5.0/86.3	-	14.8/14.9
Tumor size, cm	4.0	10	7.5
Tumor number	Multiple	Single	Single
Tumor location	Whole liver	VI/VII	Right lobe
Portal vein invasion	-	Unknown	-
Splenomegaly	-	Unknown	-
Surgery	-	Hemihepatectomy	-
Chemotherapy	+	+	-
Radiotherapy	-	-	-
Transarterial chemoembolization	-	+	-
Targeted therapy	-	-	Anlotinib
Survival, months	20	17	2
Outcome	Dead	Alive	Dead

Abbreviations: HBsAg, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; PLT, platelet count; AST, aspartate transaminase; ALT, alanine aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; PT, prothrombin time; APTT, activated partial thromboplastin time; AFP, alpha-fetoprotein; CEA, aspartate transaminase; SCC, Squamous cell carcinoma antigen; CYFRA21-1, cytokeratin19 fragment; TACE, transcatheter arterial chemoembolization.

Figure 1

Radiographical findings and pathological reports for case 1. CT scan of the abdomen revealed multiple low-density lesions in the liver accompanied by liver cysts (A and B). Pathological report revealed a diagnosis of SCC (C). IHC analysis showed that CK7 staining (D) was negative but p63 expression (E) was positive. Ventana IHC analysis (Clone NO. SP263) indicated that PD-L1 expression on tumor cells and tumor-associated immune cells was negative (F and G).

Case 2

A 47-year-old man complained of pain in the right upper region of the abdomen after drinking in October 2016. He had a history of hepatitis B but not C virus infection. He also had a long history of alcohol consumption but denied gastrointestinal bleeding history. Physical examination revealed a deep tenderness in his upper abdomen. His blood routine examination and coagulation function were normal. Liver function test showed an obvious increase in ALT, AST but TBIL and DBIL were negative. On admission, he had normal levels of AFP and CEA (Table 1). An abdominal CT scan conducted in a local hospital demonstrated a single, big and solid lesion with a diameter of 10 cm, with mild to moderate enhancement in the parenchymal part of the tumor edge. There were no lesions in his lungs, gastrointestinal tract and other organs, indicating an initial disease with localized stage. At that time, a right hepatectomy with cholecystectomy was performed when a large lesion was found in the right lobe of the liver. The final pathology report revealed a diagnosis of primary SCC of the liver through routine HE (Figure 2A) and IHC analysis (Figure 2B and C), with chronic cholecystitis. There were no stones in the bile ducts and gallbladder. The negative staining of CK7 (Figure 2B), positive staining of p63 (Figure 2C), hepatocyte and CK19 indicated the squamous epithelium origin of the tumor. Positive PD-L1 staining on tumor cells but not on tumor-associated immune cells was observed (Figure 2D and E). This patient recovered well and was consistently treated with TACE and two cycles of adjuvant chemotherapy (gemcitabine combined with 5-fluorouracil). He did not undergo radiotherapy or other therapies. This patient has a long survival time of up to 35 months and still is alive until now.

Figure 2

Pathological report revealed a diagnosis of SCC for case 2 (A). The IHC staining shows negative staining of CK7 (B) and the positive staining of P63 (C). PD-L1 expression on tumor cells was 10% (D), but its expression on tumor-associated immune cells was negative (E).

Case 3

In July 2019, A 79-year-old woman came to our hospital and presented with abdominal pain, nausea, fever and weight loss over the past 3 months. She did not have a history of hepatitis virus infection, hepatic cyst, chronic cholecystitis or hepatolithiasis. Other medical history was negative. Hematological analysis revealed liver function was normal (Table 1). The levels of CEA and AFP were normal but serum ferroprotein and SCC antigen were slightly elevated. Enhanced magnetic resonance imaging (MRI) revealed a large mass in the right lobe of the liver (7.5 × 6.0 × 5.6 cm), with a long T1 and long T2 signal, a high signal in diffusion-weighted image (DWI), and a low signal in apparent diffusion coefficient (ADC). The lesions invaded the adjacent ascending colon and surrounding peritoneum (Figure 3A–C). A US-guided fine-needle aspiration biopsy of the mass confirmed a pathological diagnosis of SCC with a histological feature of keratinization (Figure 3D–F). IHC analysis indicated that the expression of PD-L1 on tumor cells was 30%, and its expression on tumor-associated immune cells was 10% (Figure 3G and H). Both chest CT and gastrointestinal radiography reported negative findings. Therefore, a final diagnosis of primary SCC of the liver was made. Unfortunately, due to the poor performance status, the patient only received tyrosine kinase inhibitors anlotinib monotherapy and died of dysfunctions of the liver and kidneys 2 months later.

Figure 3

Radiographical findings and pathological reports for case 3. MRI revealed a large mass in the right lobe of the liver, with a long T1 and long T2 signal, a high signal in DWI, and a low signal in ADC (A–C). Pathological report revealed a diagnosis of SCC (D). The IHC analysis showed positive staining of CK5/6 (E) and P63 (F). PD-L1 expression on tumor cells was 30% (G), and its expression on tumor-associated immune cells was 10% (H).

Primary SCC of the Liver from SEER Data

There were 25 cases with primary SCC of the liver from the SEER database from 1997 to 2016. Baseline clinicopathologic features of these patients are shown in Table 2. The mean and median age was 66.4 and 67.0 years (range 33–87 years), respectively. 56.0% of patients were male and 44.0% were female. 24.0% of patients received surgery and 32.0% received chemotherapy. The median OS (Figure 4A) and disease-specific survival (DSS) (Figure 4B) were 7.7 months (range 0.0–76.0 months) and 2.0 months (range 0.0–20.0 months), respectively. Furthermore, patients receiving surgery had a longer median OS (20.0 versus 6.0 months, P = 0.016) (Figure 5A) and DSS (48.0 versus 8.0 months, P = 0.03) (Figure 5B) than those receiving palliative treatment. Only five patients survived for more than one year. It is worth reminding that the overall survival time of a 55-year-old female patient with poorly differentiated SCC of the liver was 76 months.

Table 2

Clinicopathologic Features of Primary SCC of the Liver in the SEER Database

Characteristics	No. of Patients (%)
Age, years, mean ± SD	66.4±13.2
Age, years, median (range)	67.0
Sex
Male	14 (56.0)
Female	11 (44.0)
Age (year)
≤60	9 (36.0)
>60	16 (64.0)
Race
White	14 (56.0)
Black	6 (24.0)
Other	5 (20.0)
AJCC TNM stage
I	4 (16.0)
II	2 (8.0)
III	1 (4.0)
IV	5 (20.0)
Unknown	13 (52.0)
Grade
I	1 (4.0)
II	1 (4.0)
III	7 (28.0)
Unknown	16 (64.0)
Surgery
No	19 (76.0)
Yes	6 (24.0)
Chemotherapy
No	17 (68.0)
Yes	8 (32.0)
Radiation
No	25 (100.0)
Yes	0 (0.0)

Figure 4

OS (A) and DSS (B) for all primary SCC of the liver from SEER database from 1997 to 2016.

Figure 5

OS (A) and DSS (B) for primary SCC of the liver who received surgery or palliative treatment from SEER database from 1997 to 2016.

Discussion

In this retrospective study, we reported three cases of primary SCC of the liver in a single center from 2013 to 2019 and analyzed their clinical and pathological characteristics, treatment and prognosis. We also reviewed all with the primary SCC of the liver from the SEER database from 1997 to 2016 and found that 25 patients with such disease had a median OS of 7.68 months and a median DSS of 2.00 months.

Previous studies showed that patients with primary SCC of the live presented with various symptoms including abdominal pain or discomfort, jaundice, loss of weight, loss of appetite, and rarely, progressive dysphagia. Palpable abdominal mass and tenderness over the right upper quadrant, with fever, are recognized as the most common initial signs.2 Radiographic analyses including enhanced CT and MRI help to determine the location of primary tumors, and also add useful information involving the number of lesions, their size, extent, degree of tumor invasion, whether biliary dilation occurs and whether all lesions are completely resected. Generally, the mass is mostly single, with unclear boundary, and its appearance is mostly round and lobulated. CT or MRI dynamic contrast-enhanced scan showed mild to moderate enhancement in the parenchymal part of the tumor edge, and continuous enhancement in the portal vein phase. The central necrotic area is large and unenhanced, with uneven inner edges and sometimes nodular projections of different sizes; and tumor is generally not associated with chronic liver diseases such as cirrhosis.2 The diagnosis of primary SCC of the liver is to exclude metastatic SCC of the liver from other primary sites, such as the lung, thyroid, esophagus, or gastrointestinal tract. In our cases, radiographic findings in major organs were negative and the tumors in the liver were diagnosed as primary. Primary SCC of the liver has been reported to be associated with hepatic cyst, chronic cholecystitis or hepatolithiasis in the majority of reported cases,8,11–20 and focal wall thickening of hepatic cysts or intrahepatic biliary from imaging might indicate a malignant change. However, its pathogenesis remains still uncertain. In our report, one case had a history of hepatic cysts and two cases were diagnosed with hepatolithiasis before or at the time of the confirmation of SCC of the liver. It is hypothesized that the SCC could develop from the ectopic squamous epithelium or from undifferentiated basal cells. Chronic inflammation of the bile duct or congenital cysts of the biliary tract or liver cysts associated with infection and/or stones has been attributed as the major etiological factors of malignant transformation.8,11–19 Continuous irritation due to chronic inflammation might be responsible for secondary squamous metaplasia and subsequent malignant transformation of SCC.8,11–19

Pain in the right upper region of the abdomen is the most frequently occurred symptom. However, this is not specific and should be distinguished from other primary liver or biliary tract diseases. In our cases, two patients were initially admitted with abdominal pain. In addition, altered liver function was usually observed in the primary SCC of the liver, including increased levels of ALT, AST, IBIL, and TBIL. In our reports, the second patient had increased levels of ALT and AST, but normal levels of BIL, and TBIL. Thus, the extent of liver dysfunction is associated with chronic inflammation of bile ducts, liver cyst, and cancer invasion or cancer-related obstruction of the bile duct. Unlike hepatocellular carcinoma, a specific serum tumor marker of primary SCC of the liver is not available. In our reports, all patients had normal levels of CEA and AFP, and only the second patient’s serum ferroprotein and SCC antigen were slightly elevated.

Immunohistochemically, primary SCC of the liver is positive for CK5/6, p63, and p40.2 CK19 and CK7 can be used to mark the structure of glandular ducts, which can be used to differentiate primary SCC from the neoplastic cells of the bile ductular ontogeny. Hepatocellular carcinoma is characterized by arginase-1, GPC3, hepatocytes, AFP, and cholangiocellular carcinoma was positive for CK19 and CK8. In our reports, all patients were positive for p63 and negative for CK7, hepatocyte and CK19. The third patient was positive for CK5/6, indicating that basal cells of the keratinized squamous epithelium may be the origin of the cancer cells. Furthermore, we also excluded squamous cancer from other possible sites, including lungs, thyroid, gastrointestinal tract, other than the liver, through clinical, radiological, endoscopic, and endocrine detections.

At present, there is a lack of standard of care for primary SCC of the liver. As an aggressive cancer, the prognosis of this tumor is extremely unfavorable with an OS of less than 12 months.2,6 As a rarely occurred cancer type, clinical trials associated with the treatment of this disease were not available. In previously reported cases, 42.1% of patients with surgery resection survived over 12 months. Patients with radical surgery treatment had longer overall survival compared to those with palliative treatment (median overall survival: 17 versus 5 months).2 In our reports, the second patient received radical surgery treatment and survived for 35 months. Therefore, complete surgical excision of the tumor, but not single drainage or partial excision is associated with long survival and should be recommended in the management of primary SCC of the liver. In addition, intrahepatoarterial chemotherapy and radiotherapy have been used in some patients who are not the candidates for surgery. Intrahepatoarterial chemotherapy with cis-diaminedichloro platinum and 5-fluorouracil led to a long survival time of 23 months in a primary liver SCC patient without surgery.8 Under certain circumstances, systematic chemotherapy is helpful for the treatment of advanced patients or acts as an adjuvant treatment before and after surgery. The second patient from our cohort received radical surgery treatment and survived for approximately 3 years. Interestingly, the first patient in our case series was not treated with surgery because of multiple lesions in the liver and received chemotherapy, with an OS of more than one year. Furthermore, we reported that the OS was less than 1 year for primary SCC of the liver from the SEER database from 1997 to 2016. To our knowledge, it is the first report of survival for a large number of primary liver SCC patients from SEER database. As an aggressive cancer, the prognosis of primary SCC of the liver is extremely unfavorable. In the SEER database, we found that only five patients survived for more than one year. Interestingly, patients receiving radical surgery had a longer median OS and DSS than those receiving palliative treatment. It is worth reminding that the overall survival time of a 55-year-old female patient with poorly differentiated SCC of the liver was 76 months. Thus, patients with this tumor should benefit from surgery if preoperative evaluation confirms that the tumor is surgically resectable. It is anticipated that systematic treatment can convert a selected group of patients with irresectable state into an operable state. Finally, immunotherapy with PD-1 or PD-L1 inhibitors has been approved for treating a variety of advanced human cancers, including lung squamous cell carcinoma, esophageal squamous carcinoma, cutaneous squamous cell carcinoma, and head and neck squamous cell carcinoma.20 Here we also found that two patients had positive tumor PD-L1 expression, and one patient had positive PD-L1 expression on immune cells, indicating that PD-1/PD-L1 signaling pathway may be activated. Although immunotherapy has not been a clinical therapeutic approach for primary liver SCC, PD-1/PD-L1 blockade by PD-1 inhibitors may be developed as potential agents by activating the host’s anti-cancer immune response.

Conclusion

In summary, the incidence of primary liver SCC was extremely low. The causes of carcinogenesis and etiopathogenesis need to be further studied. The prognostic factors are still unclear. Radical surgery should be firstly recommended. Chemotherapy, arterial embolization, tyrosine kinase inhibitors, and immunotherapy are potential options for the treatment of primary SCC of the liver.